Skip to main content

Advertisement

SpringerLink
Log in

Sustained hypoglycemia with therapeutic use of repaglinide

  • Case Report
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Marbury TC, Ruckle JL, Hatorp V, Nielsen KK, Huang WC, Strange P (2000) Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 67:7–15

    Article  CAS  Google Scholar 

  2. Bidstrup TB, Bjørnsdottir I, Sidelmann UG, Thomsen MS, Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human biotransformation of the insulin secretagogue repaglinide. Br J Pharmacol 56:305–314

    Article  CAS  Google Scholar 

  3. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ (2003) Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74:380–387

    Article  CAS  Google Scholar 

  4. Tomalik-Scharte D, Fuhr U, Hellmich M et al (2011) Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos 39:927–932

    Article  CAS  Google Scholar 

  5. Wei Y, Lin FJ, Lin SY, Wang CC (2019) Risk of hypoglycemia and concomitant use of repaglinide and clopidogrel: a population-based nested case-control study. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.1556

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Intensive Care, Cliniques St-Luc, Université Catholique de Louvain, Avenue Hippocrate, 10, 1200, Brussels, Belgium

    Philippe Hantson & Pierre-François Laterre

  2. Louvain Centre of Toxicology and Applied Pharmacology, Université Catholique de Louvain, 1200, Brussels, Belgium

    Philippe Hantson & Vincent Haufroid

  3. Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU de Limoges, 87042, Limoges, France

    Souleiman El Balkhi

Authors
  1. Philippe Hantson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Souleiman El Balkhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincent Haufroid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierre-François Laterre
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Philippe Hantson, Pierre-François Laterre, Vincent Haufroid and Souleiman El Balkhi. The first draft of the manuscript was written by Philippe Hantson, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Philippe Hantson.

Ethics declarations

Conflict of interest

The authors declare they have no conflict of interest.

Human and animal rights disclosure

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

A written informed consent was obtained from the patient.

Sources of funding

None.

Additional information

Managed by Antonio Secchi.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hantson, P., El Balkhi, S., Haufroid, V. et al. Sustained hypoglycemia with therapeutic use of repaglinide. Acta Diabetol 57, 751–753 (2020). https://doi.org/10.1007/s00592-019-01456-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-019-01456-w

Search

Navigation